IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS...
Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.